El-Ghiaty, Mahmoud A.
Shoieb, Sherif M.
El-Kadi, Ayman O.S.
2020-08-21T19:40:28Z
2020-08-21T19:40:28Z
2020
0306-9877
https://doi.org/10.1016/j.mehy.2020.110033
http://hdl.handle.net/20.500.12010/12104
At the end of 2019, the entire world has witnessed the birth of a new member of coronavirus family in Wuhan,
China. Ever since, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has swiftly invaded
every corner on the planet. By the end of April 2020, almost 3.5 million cases have been reported worldwide,
with a death toll of about 250,000 deaths. It is currently well-recognized that patient’s immune response plays a
pivotal role in the pathogenesis of Coronavirus Disease 2019 (COVID-19). This inflammatory element was
evidenced by its elevated mediators that, in severe cases, reach their peak in a cytokine storm. Together with the
reported markers of liver injury, such hyperinflammatory state may trigger significant derangements in hepatic
cytochrome P450 metabolic machinery, and subsequent modulation of drug clearance that may result in unexpected therapeutic/toxic response. We hypothesize that COVID-19 patients are potentially vulnerable to a
significant disease-drug interaction, and therefore, suitable dosing guidelines with therapeutic drug monitoring
should be implemented to assure optimal clinical outcomes.
7 páginas
image/jepg
eng
Medical Hypotheses
reponame:Expeditio Repositorio Institucional UJTL
instname:Universidad de Bogotá Jorge Tadeo Lozano
COVID-19
SARS-CoV-2
Cytokines
Cytochrome P450
Metabolism
Pharmacokinetics
Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms
Artículo
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
info:eu-repo/semantics/embargoedAccess
info:eu-repo/semantics/acceptedVersion
Acceso restringido
https://doi.org/10.1016/j.mehy.2020.110033
http://purl.org/coar/resource_type/c_6501